US EditionPublished • loading... • Updated
JASCAYD® (Nerandomilast) Receives First Regulatory Approval for Progressive Pulmonary Fibrosis in China
Summary by Stemwell Science News
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
Tackling pulmonary fibrosis: Boehringer Ingelheim’s new drug + AI approach - Beyond Biotech - the podcast from Labiotech
In this episode we sit down with Martin Beck, Senior Vice President and Head of the Inflammation Business Unit at Boehringer Ingelheim. Martin grew up just down the road from the company’s headquarters in Germany, joined as a scholarship student more than 20 years ago, and never really left – and...
JASCAYD® (Nerandomilast) Receives First Regulatory Approval for Progressive Pulmonary Fibrosis in China
China’s National Medical Products Administration has approved JASCAYD® as the first new treatment for adults with progressive pulmonary fibrosis in more than five years, marking a breakthrough for millions affected by the life-threatening lung condition. [Boehringer Ingelheim] Press Release
Coverage Details
Total News Sources2
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
